Ambrx Biopharma Inc (AMAM)

[reena969]

LOAD UP BEFORE MARKET CLOSE....MOONSHOT 3.0

[reena969]

30 minutes before Post market action.......NO HALTS $$$$$$$

[MT101]

Used to be $10

[bcapps66]

All this over Phase 2 results showing 57% effectiveness? This run up can't be just for the study results. This thing must have been shorted to dirt.

[MT101]

$10+ let’s get it back to its 52 week high

[MT101]

Will probably dip to $2 then run back up intraday

[reena969]

Congratulation on the profit last week. I traded TOPS instead of the 10,000% runner.

[davidsson10]

This is why we do what we do.....

[reena969]

If traders hold. that's the key ....but 700% on a nice size position....Well we know the answer

[Oger]

All time 52 week high today .
Take that to the bank

[MT101]

$10-20+ here Forsure

[Oger]

$10 plus today
Guaranteed

[reena969]

$8 High anyone?? almost 1000%

[MiamiGent]

Ambrx Shares Surge After Encouraging Early Safety, Efficacy Data From Breast Cancer Candidate

BENZINGA 9:04 AM ET Dec-09-2022

Ambrx Biopharma Inc (NASDAQ:AMAM) announced preliminary safety and efficacy data from its Phase 2 ACE-Breast-03 study.

The data presented demonstrated a 51.7% overall response rate (ORR) and 100% disease control rate (DCR) after treatment with ARX788 in HER2-positive mBC patients who are resistant or refractory to T-DM1.

ACE-Breast-03 is a Phase 2 study of ARX788 for patients whose metastatic disease is resistant or refractory to T-DXd, T-DM1, or tucatinib-containing regimens.

Related: Ambrx Biopharma Stops Working On Breast Cancer Candidate, Cites Competition As The Reason.

Patients had a median time on therapy of 7.2 months, and treatment remains ongoing.

None of the patients experienced drug-related serious adverse events (SAEs), and all adverse events (AEs) were well tolerated, with no treatment discontinuations from AEs.
Two Phase 3 studies and one registration-enabled Phase 2 study with ARX788 conducted by Amrbrx's partner, NovoCodex Biopharmaceuticals, are ongoing in China, with projected readouts in 2023.

Price Action: AMAM shares are up 180.6% at $1.15 during the premarket session on the last check Friday.
0

[MiamiGent]

AMBRX BIOPHARM Just WOW!

AMBRX BIOPHARMA INC
$2.75 +2.3401 (+570.90%)

As of Dec-09-202210:30:54 AM ET

https://stockcharts.com/h-sc/ui?s=AMAM

[makinezmoney]

$AMAM: THREE EIGHTY BABY........... SHORTS getting SMASHED !!!!!!!!!!!!!


WAH WAH WEE WAHHHHHHHHHHHHHHHHH




GO $AMAM

[ANTI-BAGHOLDER]

Nope. Crazy!

[reena969]

MM's don't have shares lol

[reena969]

Taking some profits

[reena969]

7 halts this AM after market opened $$$$$